High-flow nasal cannula therapy reduced intubation rates in critically ill Pneumocystis pneumonia patients, though survival benefits were not observed, in a multicenter retrospective analysis.

PJP was associated with high mortality and low prophylaxis rates among immunocompromised patients without HIV infection.